309 related articles for article (PubMed ID: 33749172)
1. Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.
Kalf RRJ; Vreman RA; Delnoij DMJ; Bouvy ML; Goettsch WG
Pharmacol Res Perspect; 2021 Apr; 9(2):e00742. PubMed ID: 33749172
[TBL] [Abstract][Full Text] [Related]
2. Bridging health technology assessment and healthcare quality improvement using international consortium of health outcomes measurement standard sets.
Kalf RRJ; Zuidgeest M; Delnoij DMJ; Bouvy ML; Goettsch WG
Int J Technol Assess Health Care; 2021 Dec; 38(1):e6. PubMed ID: 36317685
[TBL] [Abstract][Full Text] [Related]
3. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
[TBL] [Abstract][Full Text] [Related]
4. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
[TBL] [Abstract][Full Text] [Related]
5. Balancing adaptability and standardisation: insights from 27 routinely implemented ICHOM standard sets.
Benning L; Das-Gupta Z; Sousa Fialho L; Wissig S; Tapela N; Gaunt S
BMC Health Serv Res; 2022 Nov; 22(1):1424. PubMed ID: 36443786
[TBL] [Abstract][Full Text] [Related]
6. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
8. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
Efthymiadou O; Kanavos P
Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
[TBL] [Abstract][Full Text] [Related]
9. Common patient-reported outcomes across ICHOM Standard Sets: the potential contribution of PROMIS®.
Terwee CB; Zuidgeest M; Vonkeman HE; Cella D; Haverman L; Roorda LD
BMC Med Inform Decis Mak; 2021 Sep; 21(1):259. PubMed ID: 34488730
[TBL] [Abstract][Full Text] [Related]
10. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
Fontrier AM
Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
[TBL] [Abstract][Full Text] [Related]
11. The Critical Intersect of Regulations, Health Technology Assessment, and Drug Safety Assessments.
Yang WW; Juan YC; Wu GH; Pwu RF
Drug Saf; 2024 Apr; 47(4):289-299. PubMed ID: 38113017
[TBL] [Abstract][Full Text] [Related]
12. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
[TBL] [Abstract][Full Text] [Related]
13. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
[TBL] [Abstract][Full Text] [Related]
14. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
15. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
16. Measuring Survival Benefit in Health Technology Assessment in the Presence of Nonproportional Hazards.
Monnickendam G; Zhu M; McKendrick J; Su Y
Value Health; 2019 Apr; 22(4):431-438. PubMed ID: 30975394
[TBL] [Abstract][Full Text] [Related]
17. Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.
Vreman RA; Naci H; Goettsch WG; Mantel-Teeuwisse AK; Schneeweiss SG; Leufkens HGM; Kesselheim AS
Clin Pharmacol Ther; 2020 Aug; 108(2):350-357. PubMed ID: 32236959
[TBL] [Abstract][Full Text] [Related]
18. Building Synergy between Regulatory and HTA Agencies beyond Processes and Procedures-Can We Effectively Align the Evidentiary Requirements? A Survey of Stakeholder Perceptions.
Wang T; McAuslane N; Liberti L; Leufkens H; Hövels A
Value Health; 2018 Jun; 21(6):707-714. PubMed ID: 29909876
[TBL] [Abstract][Full Text] [Related]
19. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
[TBL] [Abstract][Full Text] [Related]
20. Regulatory, health technology assessment and company interactions: the current landscape and future ecosystem for drug development, review and reimbursement.
Wang T; McAuslane N; Goettsch WG; Leufkens HGM; De Bruin ML
Int J Technol Assess Health Care; 2023 Apr; 39(1):e20. PubMed ID: 37039100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
